Genome-wide DNA methylation meta-analysis in the brains of suicide completers by Viana, Joana et al.
Policicchio et al. Translational Psychiatry           (2020) 10:69 
https://doi.org/10.1038/s41398-020-0752-7 Translational Psychiatry
ART ICLE Open Ac ce s s
Genome-wide DNA methylation meta-analysis
in the brains of suicide completers
Stefania Policicchio1, Sam Washer1, Joana Viana1, Artemis Iatrou2, Joe Burrage1, Eilis Hannon 1, Gustavo Turecki 3,
Zachary Kaminsky4,5, Jonathan Mill 1, Emma L. Dempster1 and Therese M. Murphy1,6
Abstract
Suicide is the second leading cause of death globally among young people representing a significant global health
burden. Although the molecular correlates of suicide remains poorly understood, it has been hypothesised that
epigenomic processes may play a role. The objective of this study was to identify suicide-associated DNA methylation
changes in the human brain by utilising previously published and unpublished methylomic datasets. We analysed
prefrontal cortex (PFC, n= 211) and cerebellum (CER, n= 114) DNA methylation profiles from suicide completers and
non-psychiatric, sudden-death controls, meta-analysing data from independent cohorts for each brain region
separately. We report evidence for altered DNA methylation at several genetic loci in suicide cases compared to
controls in both brain regions with suicide-associated differentially methylated positions enriched among functional
pathways relevant to psychiatric phenotypes and suicidality, including nervous system development (PFC) and
regulation of long-term synaptic depression (CER). In addition, we examined the functional consequences of variable
DNA methylation within a PFC suicide-associated differentially methylated region (PSORS1C3 DMR) using a dual
luciferase assay and examined expression of nearby genes. DNA methylation within this region was associated with
decreased expression of firefly luciferase but was not associated with expression of nearby genes, PSORS1C3 and
POU5F1. Our data suggest that suicide is associated with DNA methylation, offering novel insights into the molecular
pathology associated with suicidality.
Introduction
Suicide represents a global public health problem, with
approximately 800,000 people dying worldwide from
suicide annually and suicide attempts up to 20 times more
frequent than completed suicide1. Moreover, suicide is the
second leading cause of death among young people
worldwide and ranks among the 20th leading causes of
death across all ages2. The risk for suicidal acts is multi-
factorial, and consists of a range of biological, psychiatric,
psychosocial, and cultural risk factors3. Despite its eco-
nomic and social burden, the underlying biological
aetiology of suicidal behaviour (SB) remains poorly
understood.
To date, large-scale genome-wide association studies
(GWAS)4–7 have failed to identify robust associations
suggesting that the risk of SB is highly polygenic in nature
and that individual gene variants are likely to account only
for a small proportion of the total phenotypic variability8.
Other factors, such as the environment, behavioural traits,
psychiatric diagnosis, lifestyle, and coping mechanisms,
are essential regulators of suicide risk and likely to
account for more sizeable effects9. Recently, increased
understanding of epigenetic processes that occur in the
brain has opened promising avenues in suicide research.
The epigenome is potentially malleable—changing with
age10, in response to specific environmental11 and psy-
chosocial factors12—providing a mechanism for the
interaction between genotype and the environment13.
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Epigenetic processes, including DNA methylation, have
recently been implicated in the aetiology of numerous
mental health disorders14–21 and SB22,23.
In the last decade, research aiming to understand the
contribution of epigenetic mechanisms to SB has impli-
cated the role for key biological pathways, including
hypothalamic pituitary adrenal axis, stress response,
polyamine system, neurotrophic signalling, and lipid
metabolism8. However, studies examining DNA methy-
lation differences associated with SB have primarily
focussed on candidate genes24–27 and few have examined
genome-wide DNA methylation changes in the brains of
suicide completers22,28. The availability of brain samples is
a major challenge for psychiatric research and many
previous studies examining DNA methylation variation in
suicide are performed on a limited number of post-
mortem brain samples22,29,30. Such small studies have
reduced statistical power to detect small changes in DNA
methylation. The objective of this study was to identify
suicide-associated DNA methylation changes in the
human brain by utilising previously published and
unpublished methylomic datasets.
Genome-wide DNA methylation profiles were available
from post-mortem brain samples of suicide completers
and non-psychiatric, sudden-death controls for a total of
seven cohorts. Methylomic data available for two different
brain regions —prefrontal cortex (PFC) and cerebellum
(CER) (PFC: 4 cohorts, n= 211; CER: 3 cohorts, n= 114)
—were meta-analysed across the suicide cohorts for each
brain region separately. We report evidence for altered
DNA methylation in suicide cases compared to non-
psychiatric controls in both the PFC and CER and
examined the functional implications of a top-ranked PFC
suicide-associated differentially methylated region (DMR)
on gene expression levels in that region. Finally, gene
ontology enrichment analysis was performed in each
brain region separately to identify pathways of genes
associated with suicide completion.
Materials and methods
Sample collection/data recruitment
For the PFC meta-analysis, we included four independent
previously published studies22,31–33 aimed at profiling DNA
methylation in human PFC in individuals with a diagnosed
axis-I psychiatric disorder and healthy non-psychiatric
controls. Only data from individuals who died by suicide
and non-psychiatric controls were included for the initial
meta-analysis. In two of the four studies selected31,32, DNA
methylation was profiled from fluorescence-activated nuclei
sorted neurones, with the remaining two studies performed
in bulk tissue22,33. Raw DNA methylation data for all four
studies are deposited in the Gene Expression Omnibus
(GEO) database (accession number: GSE89707, GSE88890,
GSE98203, GSE41826) and full details of the sample cohort
can be obtained from the original studies22,31–33. For the
CER meta-analysis, three DNA methylation datasets were
included two of which are currently unpublished
(GSE137222 and GSE137223). Raw DNA methylation data
for the CER published EWAS study33 is deposited in GEO
database (accession number: GSE89702). The unpublished
studies were approved by the University of Exeter Medical
School Research Ethics Board (REB). In all three CER
cohort’s DNA methylation profiles were derived from bulk
brain tissue and cases were individuals who died by suicide
(hanging, jumping from height, intentional poisoning, self-
harm/bleeding). Cause and manner of death as well as joint
presence of psychiatric diagnosis were determined by a
forensic pathologist after evaluating autopsy results, cir-
cumstances of death, data from extensive toxicological
testing, police reports, family interviews, and medical
records. Controls were individuals who died suddenly (e.g.
cardiac failure, viral infection, or accidents) and did not
have evidence of axis-I disorders. See Supplementary Table
S1 for a complete description of sample selection, numbers,
and demographic characteristics of each cohort.
DNA methylation analysis
DNA methylation was measured using the Illumina
HumanMethylation450K BeadChip (‘Illumina 450K array’)
or Infinium MethylationEPIC BeadChip (‘Illumina EPIC
array’, one CER cohort) platform (Illumina Inc., San Diego,
CA, USA). To ensure consistency of the methodological
approach, raw DNA methylation data (idat files) were
recovered and each cohort was independently reanalysed,
applying the same quality control (QC) and pre-processing
pipelines. Briefly, QC checks, quantile normalisation, and
separate background adjustment of methylated and unme-
thylated intensities of type I and II probes were employed
using the wateRmelon package in R34. Probes on the X- and
Y-chromosomes were used to confirm sample sex. Only
samples which passed stringent QC measures (>1% of sites
with a detection P value (P) >0.01) were included. Probes
with a detection P > 0.01 in at least 1% of samples and/or a
beadcount <3 in 5% of samples, non-specific probes,
potentially cross-reactive probes, or probes near SNPs35,36
were removed across all samples. Only probes common to
both the 450k array and EPIC array were included in
downstream analyses for the CER. For the annotation of
probes, the University of California, Santa Cruz (UCSC)
RefGene name from Illumina’s annotation file and
enhanced annotation to the UCSC Known Gene were used.
All annotations used the human February 2009 (GRCh37/
hg19) assembly.
Estimating differential neuronal proportions
The R package (available at www.cran.r-project.org),
Cell EpigenoType Specific (CETS) mapper, designed for
the quantification and normalisation of differing neuronal
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proportions in genome-wide DNA methylation datasets
was used as previously described32 to estimate brain cel-
lular heterogeneity in each of the four PFC cohorts.
Similar estimates could not be obtained for the CER
cohorts as the algorithm for the correction of brain cel-
lular heterogeneity bias was developed using post-mortem
frontal cortex data and NeuN is not expressed in CER
purkinje neurons32.
Data analysis
Statistical analyses were performed using R statistical
package (version 3.4.3). The β-value is a ratio between
methylated probe intensity and total probe intensities
(sum of methylated and unmethylated probe intensities)
and ranges from 0 to 1. Linear regression was used to
examine differences in DNA methylation scores (repor-
ted as change in β-value (Δβ)) between suicide cases and
controls at each CpG site, controlling for potential
confounders. Covariates included in all models were age,
sex, and chip. We also included ethnicity or brain bank
as covariates in the model for those cohorts where that
information was available and represented a potential
source of variation. In the PFC cohorts only, we also
adjusted for estimated neuronal proportions. For one
study22, DNA methylation differences were investigated
across individual-matched cortical regions (Brodmann
area 11 (BA11), Brodmann area 25 (BA25)) by fitting a
linear mixed-effect model (LMM) using the lme4
R package (available at https://cran.r-project.org37).
Whereby, brain region and sample ID were included in
the model as random effects (‘within participants’ fac-
tors) while diagnosis, age, sex, PH, and cellular compo-
sition were included in the model as fixed effects.
Meta-analyses
Suicide completers versus non-psychiatric controls
The results obtained from the linear regression were
then meta-analysed for each brain region independently.
A fixed-effect model, using the ‘metagen’ function in the R
package ‘meta’, was applied by providing the regression
coefficients and standard errors from each individual
cohort to calculate weighted pooled estimates and to test
for significance. Experiment-wide significance (P < 1E-07)
(threshold estimated from permutation analysis in a larger
dataset (N= 675 individuals) generated previously by our
group38) was chosen as a multiple testing threshold to
determine statistically significant DNA methylation
changes.
Suicide completers versus non-suicide psychiatric controls
In order to assess whether the observed suicide-
associated DNA methylation changes identified in our
original meta-analysis were driven by the psychiatric
disorder comorbidity rather than being suicide-specific
changes, a second exploratory analysis was performed in
additional samples obtained from the CER datasets only,
which had additional non-suicide psychiatric samples
with DNA methylation data available (not included in the
primary analysis report here). In the second meta-analysis,
each CER cohort consisted of suicide cases (that were
included in the original meta-analysis) and psychiatric
controls, where individuals had a diagnosed axis-I dis-
orders (major depressive disorders (MDD), schizophrenia
(SZ), bipolar disorder (BD)) but had no documented
evidence of SB. In total, the secondary meta-analysis
included 130 samples (case group, N= 50; psychiatric
control group, N= 80). Results obtained from the linear
regression were then meta-analysed using a fixed-effect
model as described previously.
Region-based analysis
The results obtained from both the PFC and CER meta-
analyses were used to perform a regional-based analysis
using the Python module Comb-p39 to identify suicide-
associated DMRs. The Comb-p software groups spatially
correlated DMPs (seed P < 1E-03, minimum of three
probes) at a maximum distance of 500 bp in each brain
region. DMR P were corrected for multiple testing using
Šidák correction40.
Gene ontology term enrichment analysis
A previously described logistic regression approach41
was used to test if genes (Illumina UCSC gene annotation)
annotated to probes in our PFC and CER meta-analyses
(DMPs with P ≤ 1E-04) predicted pathway membership,
while controlling for the number of probes annotated to
each gene. Briefly, pathways were downloaded from the
Gene Ontology (GO) website (http://geneontology.org/)
and all genes annotated to parent terms were also inclu-
ded. Genes containing at least one Illumina probe and
annotated to at least one GO pathway were considered.
Pathways were filtered to those containing between 10
and 2000 genes and a list of significant (after correction
for multiple testing—Bonferroni correction) pathways
were identified as previously described41.
Functional follow-up of significant DNA methylation
findings
Tissue (N= 71) from two regions of the cortex, BA11
(N= 38) and BA25 (N= 33), collected from 20 MDD suicide
cases and 20 non-psychiatric sudden-death controls was
obtained from the Douglas Bell Canada Brain Bank (DBCBB)
(http://douglasbrainbank.ca/), further details are available in
ref. 22. Previously, our group performed DNA methylation
profiling in these samples22 and the results of that study were
included in this meta-analysis study. To examine whether
our identified suicide-associated DMR (PSORS1C3 DMR;
Chr6:31,148,370-31,148,553 (Hg19), 2694 bp downstream
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the TSS of PSORS1C3 gene) is associated with the expression
of nearby genes, we measured expression levels of two nearby
genes in these brain tissue samples. We tested for an asso-
ciation with gene expression firstly at the closest transcrip-
tion start site (TSS) gene—the lncRNA gene, PSORS1C3—
and then at the second closest gene, POU5F1 (see Supple-
mentary Fig. S1 for details).
Gene expression analysis
Thirty milligrams of frozen PFC tissue from each brain
sample was homogenised with Qiazol Lysis Reagent (Qia-
gen, Valencia, CA, USA), as per the manufacturer’s
instructions, before running it through a QIAshredder
(Qiagen, Valencia, CA, USA). Total RNA was extracted
using the Qiagen miRNeasy Mini column-purification sys-
tem and treated with DNase I as outlined by the manu-
facturer. The Agilent 2100 Bioanalyzer was used to check
the quality and concentration of the extracted RNA sam-
ples. One microgram of total RNA was reverse transcribed
into complementary DNA (cDNA) (20 μL reactions)
according to the manufacturer’s instructions using the
Invitrogen VILO cDNA synthesis kit (Life Technologies
Ltd, Paisley, UK). Three housekeeping genes Ubiquitin
Conjugating Enzyme E2 D2 (UBE2D2), Cytochrome C1
(CYC1), and Ribosomal Protein L13 (RPL13) identified
previously42 as being among the most stably expressed in
the brain were selected to normalise the target gene
expression. Next, quantitative RT-PCR was performed in
triplicate for each assay using the StepOnePlus Real-Time
PCR machine (Applied Biosystems, Foster City, Calif) and
pre-optimised Taqman gene expression assays (Applied
Biosystems, Foster City, Calif). A full list of the qPCR assays
used is given in Supplementary Table S2. PCR cycling
conditions were as follows: 50 °C for 2min, 95 °C for 20 s,
and 40 cycles of 95 °C for 10 s, and 60 °C for 20 s. We
undertook stringent QC of raw qPCR data, repeating
samples where there was high variability between triplicates
(Ct > 0.5). The abundance of each test gene was determined
by the comparative Ct method43, expressed relative to the
geometric mean of the three housekeeping genes. Data were
log2-transformed to ensure normal distribution and pre-
sented as a fold-difference in expression of suicide cases
relative to controls using the 2−ΔΔCT method. To assess
whether POU5F1 expression levels were associated with a
history of suicide, we used a LMM using the lme4 R
package (available at https://cran.r-project.org)37 where ΔCt
values of the target gene (POU5F1) was the response vari-
able. Brain region and sample ID were included in the
model as random effects (‘within participants’ factors) while
diagnosis, age, sex, and neuronal proportion were included
in the model as fixed effects. Finally, since 450K array data
were available from the same individuals, we examined the
correlation between gene expression levels and mean DNA
methylation levels at the DMR.
Reporter constructs
The PSORS1C3 DMR sequence was inserted into the
pCpGL-basic vector (see ref. 44 for details), which is
devoid of CpG sites and was generously provided by the
Rehli laboratory44. Briefly, the cleaned PSORS1C3 PCR
amplicon was inserted into a digested pCpGL-basic
plasmid using T4 ligase and buffer (Invitrogen, Cali-
fornia, USA). Ligated plasmids were transformed into
One Shot PIR1 E. coli (ThermoFisher Scientific, Massa-
chusetts, USA) to allow for monoclonal amplification of
the recombinant plasmids. For the transformation, 50 µl
of One Shot PIR1 E. coli was used, including a negative
ligation control and a positive transformation control
(pUC19) using standard procedures.
Clones were subsequently checked by clonal PCR,
restriction digest using BglII and NcoI and Sanger
sequencing (see Supplementary Fig. S2) to confirm the
DMR had been inserted in the correct orientation. The
pCpGL construct was methylated in vitro using M.sssI
methyltransferase (New England Biolabs, Massachusetts,
USA) in the presence of S-adenosylmethionine (SAM)
following the manufacture’s protocol. An empty pCpGL-
basic vector was also methylated to act as a control. To
confirm successful methylation, the plasmids underwent
digestion with the methylation sensitive enzyme HpaII
(see Supplementary Fig. S3).
Cell culture and transfections in HEK293 cells were
cultured in Dulbecco’s modified Eagle’s medium (þ4.5 g
l_1 D-glucose, L-glutamate, pyruvate) (Gibco) with 10%
foetal bovine serum (Gibco) at 37 °C and 5% CO2. Briefly,
2 × 105 cells were seeded in six-well plates. The following
day media was removed, the cells washed with PBS, and
1.5 ml of fresh growth media was added. Five hundred
nanograms of PSORS1C3 or pCpGL plasmid and 100 ng
of pGL4.74[hRluc/TK] reporter control vector (Promega,
Wisconsin, USA) were diluted in 500 µl of Opti-MEM
reduced serum media (Gibco, Massachusetts, USA) in an
Eppendorf and left to equilibrate for 5 min at room
temperature. In all, 4.5 µl of Lipofectamine LTX Reagent
(ThermoFisher Scientific, Massachusetts, USA) was then
added to each Eppendorf and incubated for 30min at
room temperature. Following incubation, 500 µl of LTX
plasmid mix was added to the HEK293 cells in six-well
plates. Cells were then incubated at 37 °C, 5% CO2, for
24 h to allow expression of firefly and Renilla luciferases.
Dual-luciferase assay
Twenty-four hours following transfection a dual-
luciferase reporter assay (Promega, Wisconsin, USA)
was carried out to measure the expression of firefly luci-
ferase and Renilla luciferase in the transfected cells as per
the manufacturers’ instructions. Each experiment con-
tained three technical repeats and the experiment was
repeated three times. The injections and light absorbance
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were carried out automatically using the pherastar plate
reader. The average firefly luciferase activity was calcu-
lated by averaging absorbance readings between 2 and
10 s. The average Renilla luciferase activity was calculated
by averaging absorbance readings between 14 and 22 s.
Data analysis was carried out as described in ref. 45. All
data are presented as a normalised firefly luciferase
activity relative to Renilla luciferase. Fold change
expression was calculated by dividing the unmethylated
normalised firefly luciferase activity by the respective
methylated normalised luciferase activity. A Student’s
T-test was used to compare the methylated versus
unmethylated vectors.
Results
Suicide-associated DMPs in human cortex and cerebellum
An overview of the methodological approach used in this
study is given in Supplementary Fig. S4. We identified one
DMP (cg00963169) in the PFC, which reached experiment-
wide significance (P= 3.30E-08 (Fig. 1a)). The effect size at
this CpG site, located downstream of exon 1 of the neuron-
specific protein coding gene, ELAV-like RNA binding pro-
tein 4 (ELAVL4), was largely consistent across all cohorts
included (see Supplementary Fig. S5), showing hypomethy-
lation in suicide cases relative to controls. Interestingly, the
20 most significant (P < 5E-05) suicide-associated differen-
tially methylated loci identified in the PFC, listed in Sup-
plementary Table S3, include probes in the vicinity of several
loci previously implicated in psychiatric phenotypes. In the
CER, six probes (cg14392966, cg17855963, cg25590492, cg
12284382, cg10757978, cg04525580) passed the experiment-
wide significance threshold (P < 1E-07) (Fig. 1b). Of interest
the top-ranked DMP, cg14392966 (P= 3.06E-11), which is
located within the coding region (exon 1) of the PUS3 gene
on Chr11, has been previously associated with severe neu-
rodevelopmental disorders46. Supplementary Figure S6
shows that this DMP is hypomethylated in two of the three
cohorts in suicide cases compared to healthy controls. A list
of the top 20 DMPs in the CER is provided in Supplementary
Table S4.
Region-based analysis of altered DNA methylation in
suicide completers
We used the python module, Comb-p39, to identify
DMRs in suicide cases compared to controls in each brain
region. The regional analysis identified three and eight
significant (Sidak-corrected P < 0.05) DMRs in the PFC
and CER, respectively (see Table 1 for details). In the PFC,
the top-ranked DMR was found within the WRB gene
(Sidak-corrected P= 5.11E-06) and was consistently
hypomethylated across all five CpG sites in suicide cases
relative to controls, in all four PFC methylomic studies
(Fig. 2). Of interest, the second top-ranked suicide-asso-
ciated DMR in the PFC (Sidak-corrected P= 3.81E-05)
was located downstream of the promoter region of
the PSORS1C3 non-coding gene, a DMR previously
Fig. 1 Suicide-associated DMPs in human cortex and cerebellum. Manhattan plot showing site-specific genome-wide pattern of DNA
methylation in a the human prefrontal cortex (PFC) and b the human xerebellum (CER). One CpG site was identified as differentially methylated
between suicide cases and healthy controls at experiment-wide significant (P= 1E-07) in the PFC. Six CpG sites were identified as differentially
methylated between suicide cases and healthy controls at experiment-wide significant (P= 1E-07) in the CER.
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reported by our group as associated with MDD suicide
completers22.
In the CER, the top-ranked suicide-associated DMR was
identified on chromosome 22, distributed along the
intronic region of the CERC2 gene and spanning 4 CpG
sites. The CERC2-associated DMR (Fig. 3) showed sig-
nificant hypermethylation (Sidak-corrected P= 5.68E-07)
across all 4 CpG sites within the region in suicide cases
compared with controls. The direction of this change was
found to be consistent across all 3 CER methylomic
studies.
Pathway analysis
The biological relevance of our findings was investigated
through gene ontology analysis on genes annotated to
suicide-associated DMPs (P ≤ 1E-04). Results revealed an
enrichment of DNA methylation alterations in genes
involved in cognitive processes such as long-term synaptic
depression and brain development (See Supplementary
Table S5 and S6).
Suicide-associated DMPs identified in the CER are largely
independent of comorbid psychiatric disorders
In order to disentangle the relative contribution of
psychopathologies from DNA methylation changes spe-
cific to suicide, we performed an additional meta-analysis
in the CER whereby all the non-psychiatric controls
initially included in our meta-analysis were excluded and
individuals with documented Axis-I psychiatric disorders
(MDD, SZ, BD) and who died by suicide were compared
to psychiatric cases without a documented history of SB/
suicide fatalities (3 cohorts, N= 130, cases N= 50, con-
trols N= 80). Comparison of the results (effect sizes at the
top 500 (P < 0.05) DMPs) from our original CER meta-
analysis and the secondary analysis (Supplementary
Fig. S7) revealed a strong positive correlation (P= 2.2E-
16; R= 0.89). Moreover, 2 of the 6 CER-associated DMPs
(P < 1E-07) were nominally significantly differentially
methylated in our suicide cases versus psychiatric controls
analysis (cg10757978, P= 1.19E-04; cg04525580, P=
0.017) (see Supplementary Table S7 for details) and a
similar direction of effect was observed for both analyses
for the remaining 4 CER-associated DMPs. We were
unable to perform the same analysis in the PFC due to
lack of samples from individuals with an axis-I diagnosis
who did not die by suicide.
Functional validation and gene expression analysis of the
PSORS1C3 DMR
Given our replication of a PSORS1C3 DMR in suicide22
we aimed to functionally evaluate its effect on the
expression of nearby genes. First, we examined the effect
of DNA methylation at the suicide-associated DMR on
nearby gene expression using a CpG-Free Luciferase
Reporter (pCpGL vector) gene assay47. Next, we examined
gene expression levels of nearby annotated genes
(PSORS1C3 and POU5F1) in a subset of samples for
which brain tissue was available (two brain regions (BA11
and BA25, N= 70; suicide cases (N= 36), non-psychiatric
controls (N= 34)) and examined the correlation between
expression levels of our selected target genes and mean
DNA methylation at the suicide-associated DMR.
We found a marked increase in the relative expression
of firefly luciferase activity normalised to Renilla luciferase
in the unmethylated PSORS1C3 cloned pCpGL vector
compared to the methylated vector (Fig. 4) (fold change
= 206, P= 0.006, N= 3). Next, we quantified gene
expression levels of the PSORS1C3 long non-coding gene
Table 1 Comb-p differentially methylated region (DMR) analysis.
Brain region Hg19 Annotated gene (UCSC) No. of probes Slk P value Sidak P value
PFC chr21:40759534-40759695 WRB 5 2.02E-09 5.11E-06
chr6:31148370-31148553 PSORS1C3 10 1.71E-08 3.81E-05
chr22:38071168-38071189 LGALS1 3 3.37E-08 0.0006529
CER chr22:17956453-17956561 CECR2 4 1.55E-10 5.68E-07
chrX:79590789-79590956 CHMP1B2P 4 3.74E-09 8.84E-06
chr13:99100506-99100587 FARP1 3 2.68E-09 1.31E-05
chr6:31838402-31838529 SLC44A4 5 2.68E-08 8.32E-05
chr3:149374761-149374915 WWTR1 3 7.56E-08 0.0001938
chr12:116756805-116756949 MED13L 3 8.64E-08 0.0002369
chr1:1846046-1846155 CALML6 3 9.40E-08 0.0003406
chr11:2397486-2397686 CD81-AS1 4 2.10E-06 0.004138
CER cerebellum, PFC prefrontal cortex, Hg19 human genome version 19, UCSC University of California, Santa Cruz Human Genome Browser. Stouffer-Liptak-Kechris
correction (slk); one-step Siidak (1967) multiple testing correction.
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in a cohort of 70 post-mortem brain samples (BA11, N=
38; BA25, N= 32, both regions obtained from the same
individuals). Our analysis showed that in our sample set,
PSORS1C3 lncRNA was not expressed in the PFC
(Ct Value >31 or undetermined). This result is con-
sistent with findings in Genotype-Tissue Expression
(GTEx) portal48 (https://www.gtexportal.org/home/
gene/PSORS1C3), which shows little to no expression
for this gene in brain samples examined. Next, we
examined expression levels of the second closest gene
(POU5F1) to the suicide-associated DMR. An LMM was
used to compare mean dCt values between suicide cases
and non-psychiatric controls and the analysis showed no
significant difference in gene expression levels between
the two groups (P= 0.598; Supplementary Fig. S8A).
Furthermore, we found no significant correlation
between mean DNA methylation at the suicide-
associated region PSORS1C3 DMR and POU5F1 gene
expression levels (Pearson’s R=−0.04, P= 0.67; Sup-
plementary Fig. S8B).
Discussion
In this study, we utilised previously published and
unpublished methylomic datasets to perform a meta-
analysis of variable DNA methylation in the brain of
suicide completers. DNA methylation data were available
for two different brain regions (PFC: 4 cohorts, N= 211;
CER: 3 cohorts, N= 114) and data were meta-analysed
across the suicide cohorts for each brain region separately.
To our knowledge, this represents the most extensive
Fig. 2 Suicide-associated differentially methylated region (DMR) in human Prefrontal cortex (PFC). Plot showing the top-ranked DMR in the
PFC. This DMR, spanning 5 CpG sites and located in the promoter region of the WRB gene (Sidak-corrected P= 5.11E-06), was found consistently
hypomethylated in suicide cases compared to healthy controls, across all 4 suicide brain cohorts. The solid line is for illustration purposes and not
indicative that the CpG sites between sites are also methylated.
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methylomic study of suicide completers using post-
mortem brain tissue to date.
While several studies suggest the involvement of the
PFC in SB22,49–51, suicide-associated epigenetic changes in
the CER have not been investigated. However, the CER is
known to play an important role in motor control, cog-
nition, and emotional processing and is involved in a
variety of psychiatric disorders, including depression,
bipolar disorder, and schizophrenia52. Suicidal behaviour
in those with depression has been associated with a
decreased cerebellar volume53 and low regional cerebral
blood flow in the cerebellum54. Moreover imaging studies
have reported structural abnormalities associated to sui-
cide attempt in MDD in cortical and subcortical regions,
including cerebellum55 and alterations in functional
cerebellum networks were found in depressed patients
with a suicide attempt history56. Altogether these studies
support the hypothesis of a potential involvement of CER
in the psychopathology of attempted suicide in patients
with MDD. We set out to further explore the role of DNA
methylation and suicidality in this region as well as to
determine if suicidality associated DNA methylation
changes are brain region specific.
We first examined site-specific genome-wide patterns of
DNA methylation in suicide cases compared with controls
in the PFC and CER separately. We identified one DMP
(cg00963169, P= 3.30E-08) in the PFC, which reached
experiment-wide significance. This probe, located in the
intronic region of the ELAVL4 gene, shows consistent
hypomethylation in suicide cases compared to controls.
Fig. 3 Suicide-associated differentially methylated region (DMR) in human Cerebellum (CER). Plot showing the top-ranked DMR in the CER.
This DMR, spanning 4 CpG sites and located within the coding region of the CECR2 gene (Sidak-corrected P= 5.68E-07), was found consistently
hypermethylated in suicide cases compared to healthy controls, across 3 suicide brain cohorts. The solid line is for illustration purposes and not
indicative that the CpG sites between sites are also methylated.
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The ELAVL4 gene has a known role in translation and
stabilisation of mRNA, especially in the brain, and acts as
a negative regulator of proliferation, activity, and differ-
entiation in neural stem cells57,58. Through their mRNA
stabilising activities, this family of proteins modulate
neuronal development and maintenance, and their altered
activity has been implicated in neurological conditions59
and disorders including Alzheimer’s disease60, schizo-
phrenia61, and autism62. Of interest, the association with
suicide at this site was found to be largely driven by PFC
cohorts derived from neuronal nuclei (see Supplementary
Fig. S5) and thus future replication of this finding in
sorted neuronal cells may yield more significant associa-
tions with suicide.
In the CER, we identified six probes (cg14392966,
cg17855963, cg25590492, cg12284382, cg10757978, cg
04525580) at experiment-wide significance threshold (P <
1E-07). The top-ranked DMP, cg14392966 (P= 3.06E-11), is
located in exon 1 of the PUS3 gene. PUS3 encodes a highly
conserved enzyme responsible for post-transcriptional
modification of tRNA and has previously been associated
with intellectual disability63 and severe neurodevelopmental
disorders46. The remaining DMPs include probes in the
vicinity of several loci previously implicated in pathways
relevant to psychiatric phenotypes. For example, ZIC1 is
thought to play an important role in neurogenesis and cer-
ebellum differentiation64, whereas RASD2 is known to
modulate dopaminergic neurotransmission65. Furthermore,
the probe cg04525580 (P= 9.08E-08) is located at the 5′
UTR of the interferon regulatory factor 2 (IRF2) gene. This
locus plays an important role in transcriptional activation at
promoters66 and regulates the expression of a variety of
genes involved in immune responses in the brain67, further
supporting a role for immune-related pathways in suicide.
To increase the power of our study to identify changes
in DNA methylation between cases and controls and
given that DNA methylation at adjacent probes is often
correlated, we employed the regional-based analysis,
Comb-p, to identify DMRs. Our analysis identified three
and eight significant (Sidak-corrected P < 0.05) DMRs in
the PFC and CER, respectively. In the PFC, the top-ranked
DMR, located in intron 1 of the WRB gene, is consistently
hypomethylated across all five CpG sites in suicide cases
relative to controls, in all cohorts. Recent studies suggest a
role for Wrb in photoreceptor synaptic transmission in
zebrafish68 and the WRB locus was reported among the
differentially expressed genes in a mouse model study
looking at cognitive impairment and neuropathology in
Down syndrome brain69 further supporting the hypoth-
esis of its involvement in the correct development and
functioning of the CNS.
The second top-ranked suicide-associated DMR in the
PFC (Sidak-corrected P= 3.81E-05) was located down-
stream the promoter region of the PSORS1C3 non-coding
gene, a DMR previously reported by our group as asso-
ciated with MDD suicide completers22. Although the
Fig. 4 Methylation of the PSORS1C3 cloned pCpGL vector significantly reduces luciferase activity. There is a significant increase in firefly
luciferase expression when normalised to Renilla luciferase, the normalised expression ratios of firefly activity increases to 3.81 when unmethylated
versus 0.0269 when methylated in vitro (Students t-test, P= 0.0057, n= 3) which corresponds to a 206-fold change increase in luciferase activity in
the unmethylated PSORS1C3 cloned vector compared to the methylated identical vector. N= 3 experimental repeats with each experiment
containing three technical repeats. Error bars represent ± the standard error.
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function of this gene product remains unclear, it is
thought to be a potential regulator of nearby immune-
related genes70 and is a known risk gene for psoriasis71,72,
supporting a role in immune system regulation. To gain
further insight into the role of this suicide-associated
PSORS1C3 DMR on nearby gene expression, we first used
a dual-luciferase assay to determine if DNA methylation
at this region decreases expression of firefly luciferase in a
CpG-free vector. The methylated PSORS1C3 DMR con-
struct was significantly associated with decreased
expression of the reporter gene product, indicating that
the methylation status of this DMR has the potential to
modify promoter activity; however, the identity of the
modified gene product is unknown. We found no evi-
dence of suicide-associated differential gene expression of
nearby genes, PSORS1C3 and POU5F1, in the PFC. We
hypothesise that DNA methylation changes at this
suicide-associated DMR are associated with a different
nearby gene or an unknown splice variant of either the
PSORS1C3 or POU5F1 genes. Finally, an additional DMR
was identified in the PFC, located on chromosome 22, in
the promoter region of the LGALS1 gene. This gene is
thought to play a role in immune system functioning65
and DNA methylation changes at this locus have pre-
viously been implicated in schizophrenia33.
In the CER, the top-ranked suicide-associated DMR,
located in the intronic region of the CERC2 gene on
chromosome 22, spans four CpG sites. This locus is
known to be involved in the control of the periodic
oscillation of cyclin E expression in proliferating cells likely
through its histone deacetylase activity73. The CERC2-
associated DMR showed significant hypermethylation
(Sidak-corrected P= 5.68E-07) across all four CpG sites
within the region in suicide cases compared with controls
and the direction of this change was found to be consistent
across all three independent CER methylomic studies. To
the best of our knowledge, this gene has not been pre-
viously implicated in the pathology of SB. Seven additional
suicide-associated DMRs were identified in the CER. Of
interest is the DMR located in exon 10 of the SLC44A4
gene; a gene recently implicated in a study looking at the
role of the major histocompatibility complex region in
schizophrenia susceptibility74. An additional suicide-
associated DMR, worthy of further investigation, is loca-
ted in exon 3 of the WWTR1 gene, a transcriptional
coactivator known for its role in preserving neuronal
health75. Furthermore, a missense variant in this gene was
recently associated with lower cognitive ability in a GWAS
study for infant mental and motor ability76. Finally, we
identified a suicide-associated DMR located downstream
the promoter region ofMED13L gene and genetic variants
at this locus have been widely reported as associated with
intellectual disability77,78, suggesting that this gene may
play an important role in neurological development.
Since SB is often a complication of a psychiatric dis-
order, distinguishing suicide diathesis-related DNA
methylation changes from those associated with mood
disorders and other psychiatric disorders has remained a
challenge. In order to unravel the relative contribution of
psychopathologies from DNA methylation changes spe-
cific to suicide, we performed an additional meta-analysis
in the CER whereby individuals with documented Axis-I
psychiatric disorders (MDD, SZ, BD) and who died by
suicide were compared to psychiatric cases without a
documented history of SB. Comparison of the results
(effect size of the top 500 nominally significant (P < 0.05)
DMPs) from our original CER meta-analysis and the
secondary analysis revealed a strong positive correlation
(P= 2.2E-16; R= 0.89). Moreover, we replicated our
findings for two of the six CER-associated DMPs, which
reached multiple testing threshold in our suicide cases
versus psychiatric controls meta-analysis (cg10757978,
P= 1.19E-04; cg04525580, P= 0.017) and we observed
similar direction of effect for the remaining loci. Taken
together these findings suggest that suicide-associated
DMPs identified in the CER are largely independent of
comorbid psychiatric disorders. Unfortunately, we were
unable to perform the same analysis in the PFC due to the
limited number of samples that did not die by suicide but
had an Axis-I diagnosis.
Despite the power of the methodological approaches
used in this study, there are several caveats. First, the
modest number of studies included made this meta-
analysis relatively underpowered to detect small changes
in DNA methylation. Despite this we were able to identify
several statistically significant DMPs and DMRs in both
brain regions. Another major limitation is that bulk brain
tissue was used in most of the studies included in our
meta-analysis and cellular heterogeneity is a well-known
confounder in DNA methylation studies. In order to
bypass this issue, we used a previously reported in silico
method to estimate the neuronal proportion in each
sample in bulk PFC cohorts and included these estimates
in the statistical models32. This method could not be
applied to our analysis of the CER and thus it is plausible
that cellular heterogeneity is confounding some of our
CER results. Third, recent research has implicated
the importance of other DNA modifications (i.e., 5-
hydroxymethyl cytosine) in the brain79. Our measure of
DNA methylation in this study cannot be distinguished
from 5-hydroxymethyl cytosine (5hmC). Of interest, we
examined the presence of detectable 5hmC levels at sta-
tistical significant DMPs identified in this study in their
respective brain regions using the Hydroxymethylation
Annotation in Brain Integrative Tool (HABIT) tool
(http://epigenetics.iop.kcl.ac.uk/HMC/)41. This tool iden-
tified detectable levels of 5hmC at the following suicide-
associated DMPs cg00963169 (PFC), and cg17855963 and
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cg04525580 (CER), suggesting that the majority of DMPs
identified in this study are not confounded by 5hmC.
However, future studies should attempt to examine the
role of 5hmC in SB. Fourth, medication data, smoking
information, and method of suicide were not available for
all individuals; thus, we cannot rule out the possibility that
the observed DNA methylation changes are influenced by
these potential confounders.
Fifth, we acknowledge the possibility that many of the
associations reported (DMPs/DMRs) could be related to
the severity and/or duration of the mental health disorder.
From our secondary analysis in the cerebellum we show
that for certain top-ranked DMPs the association appears
to be suicide associated rather than associated with the
underlying mental health disorder. Given the lack of
information related to severity and/or duration of mental
illness for samples included in this meta-analysis we
cannot rule out the contribution of the above-mentioned
confounders.
Finally, although our study presents evidence for novel
DNA methylation changes associated with suicide, further
replication using a larger sample size is required to sup-
port these results. In addition, future studies could also
examine the transcriptional consequences of the observed
DNA methylation changes at the PSORS1C3 DMR on
additional nearby genes and/or novel splice variants in the
region. There is considerable interest in using DNA
methylation-based biomarkers as predictors for suicide
risk and previous studies30,80–84 have identified poly-
morphic CpGs that can act as a unique molecular sig-
nature for suicide prediction. The data from this study
provide many more candidate regions as potential bio-
markers for suicide risk and also identifies genes/networks
potentially dysregulated in suicidal brain.
In summary, our data, which utilise several published
and unpublished suicide cohorts, have identified DMPs
and several DMRs associated with suicide in both the
PFC and CER, including the previously identified DMR
upstream of the PSORS1C3 non-coding gene. We show
that this DMR can influence gene expression using a dual-
luciferase assay, but we have yet to identify its target gene.
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